Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Total Liabilities (2017 - 2025)

Entera Bio has reported Total Liabilities over the past 9 years, most recently at $2.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 120.76% year-over-year to $2.9 million, compared with a TTM value of $2.9 million through Dec 2025, up 120.76%, and an annual FY2025 reading of $2.9 million, up 120.76% over the prior year.
  • Total Liabilities came in at $2.9 million for Q4 2025, up from $2.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $10.9 million in Q1 2021 to a low of $1.2 million in Q3 2022.
  • Median Total Liabilities over the past 5 years was $2.2 million (2023), compared with a mean of $2.5 million.
  • The sharpest move saw Total Liabilities crashed 76.48% in 2022, then soared 120.76% in 2025.
  • Over 5 years, Total Liabilities stood at $3.4 million in 2021, then plummeted by 59.88% to $1.4 million in 2022, then rose by 0.44% to $1.4 million in 2023, then decreased by 5.0% to $1.3 million in 2024, then soared by 120.76% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Total Liabilities are $2.9 million (Q4 2025), $2.2 million (Q3 2025), and $2.4 million (Q2 2025).